索引于
  • 学术期刊数据库
  • 打开 J 门
  • Genamics 期刊搜索
  • 期刊目录
  • 中国知网(CNKI)
  • 西马戈
  • 乌尔里希的期刊目录
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-WorldCat
  • 普布隆斯
  • 米亚尔
  • 大学教育资助委员会
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • 谷歌学术
分享此页面

抽象的

The Current State of Safety of Allergen Immunotherapy

Cristoforo Incorvaia*, Francesco Pucciarini, Bruena L. Gritti, Alessandro Barone, Erminia Ridolo

Allergen Immunotherapy (AIT) is aimed at treating allergy by modifying the immunological response to allergens. However, administration of the causative allergen by Subcutaneous Immunotherapy (SCIT) to a sensitized patient may result in severe, and rarely fatal, systemic reactions. The identification of risk factors for anaphylaxis, especially concomitant uncontrolled asthma, has led to a significant reduction, but not yet elimination, in fatalities. The option of Sublingual Immunotherapy (SLIT) has been shown to be safer, with no fatalities reported thus far and including rare episodes of anaphylaxis, but the fact that the treatment is self-administered by the patient requires precautions and careful education.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证